137 related articles for article (PubMed ID: 9558370)
1. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F
Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370
[TBL] [Abstract][Full Text] [Related]
2. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
3. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation.
de Fabritis P; Amadori S; Petti MC; Mancini M; Montefusco E; Picardi A; Geiser T; Campbell K; Calabretta B; Mandelli F
Leukemia; 1995 Apr; 9(4):662-4. PubMed ID: 7536864
[TBL] [Abstract][Full Text] [Related]
4. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
[TBL] [Abstract][Full Text] [Related]
6. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study.
Luger SM; O'Brien SG; Ratajczak J; Ratajczak MZ; Mick R; Stadtmauer EA; Nowell PC; Goldman JM; Gewirtz AM
Blood; 2002 Feb; 99(4):1150-8. PubMed ID: 11830460
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
8. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
Liu J; Jiang J; Zhang Y; Wu D; Yang G; Huang X; Wei X
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):599-601. PubMed ID: 12528561
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia.
Clark RE; Grzybowski J; Broughton CM; Pender NT; Spiller DG; Brammer CG; Giles RV; Tidd DM
Bone Marrow Transplant; 1999 Jun; 23(12):1303-8. PubMed ID: 10414920
[TBL] [Abstract][Full Text] [Related]
10. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Skorski T; Nieborowska-Skorska M; Barletta C; Malaguarnera L; Szcyzlik C; Chen ST; Lange B; Calabretta B
J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
12. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
[TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Gewirtz AM
Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
[TBL] [Abstract][Full Text] [Related]
15. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
de Fabritiis P; Amadori S; Calabretta B; Mandelli F
Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
[TBL] [Abstract][Full Text] [Related]
17. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.
Corsetti MT; Lerma E; Dejana A; Cavaliere M; Figari O; Vassallo F; Abate M; Luchetti S; Piaggio G; Parodi C; Li Pira G; Manca F; Carella AM
Exp Hematol; 2000 Jan; 28(1):104-11. PubMed ID: 10658682
[TBL] [Abstract][Full Text] [Related]
19. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
[TBL] [Abstract][Full Text] [Related]
20. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
